Results 151 to 160 of about 90,958 (327)

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

The Cosmetics Europe strategy for animal-free genotoxicity testing: Project status up-date

, 2013
Stefan Pfuhler, Rolf Fautz, Gladys Ouédraogo, Arnaud Latil, Julia Kenny, Claire E. Moore, W. Diembeck, Nicola J. Hewitt, Kerstin Reisinger, José G. Barroso   +9 more
openalex   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

In the Beast Mode: Predator Self-Identifications as a Model of Disagreeable Functioning. [PDF]

Assessment
Robinson MD, Irvin RL, Asad MR.
europepmc   +1 more source

Onsite performance testing of Archimedes hydropower screw for low head and ultra-low head hydro power project– A case study

Deepak S. Pillai, Christopher Stephen, Durgesh K. Tiwari, Manish Kr. Singh   +3 more
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Morphometric Analysis of Mandibular Ramus Indices for Sex Prediction Using Digital Orthopantomograms (OPGs) and the GNU Image Manipulation Program (GIMP) Software. [PDF]

Cureus
Thube HR, Vaswani V, Chandwani N, Shrigiriwar M.   +3 more
europepmc   +1 more source

Seismic reflection surveys before and after BEXAR at the Nevada Test Site. Los Alamos Source Region Project: Final report

, 1992
Richard T. Miller, Don W. Steeples
openalex   +2 more sources

Stress corrosion crack initiation testing with tapered specimens in high-temperature water – results of a collaborative research project [PDF]

, 2020
Rik-Wouter Bosch, Stefan Ritter, Matthias Herbst, R. Kilian, M.G. Burke, Jonathan Duff, Fabio Scenini, Yuchen Gu, Alice Dinu, Ulla Ehrnstén, Aki Toivonen, Radek Novotný, Oliver Martin, Francisco-Javier Perosanz, Andraž Legat, Bojan Zajec   +15 more
openalex   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source